Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL R MIGDEN

Allopathic & Osteopathic Physicians Dermatology

NPI
1528008836
CMS profile
1260054
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$64,594.97

69 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $41,894.84 18
Travel and Lodging $20,344.23 25
Food and Beverage $1,455.90 25
Education $900.00 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–69 of 69 matching records. This page contains 19 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL R MIGDEN

NPI 1528008836 · CMS profile ID 1260054

Allopathic & Osteopathic Physicians / Dermatology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–69 of 69 matching records. This page contains 19 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1528008836?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL R MIGDEN, NPI 1528008836, CMS profile ID 1260054. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–69 of 69 matching records. This page contains 19 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1528008836?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MICHAEL R MIGDEN, NPI 1528008836, CMS profile ID 1260054. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–69 of 69 matching records. This page contains 19 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1528008836?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MICHAEL R MIGDEN, NPI 1528008836, CMS profile ID 1260054, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–69 of 69 matching records. This page contains 19 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1528008836?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

69 matching records · $64,594.97 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 69 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–69 of 69.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $16.4906/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200768618 CMS
Regeneron Pharmaceuticals, Inc. $940.0005/16/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1213241083 CMS
Regeneron Pharmaceuticals, Inc. $940.0005/16/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1213241085 CMS
Regeneron Pharmaceuticals, Inc. $470.0005/16/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1213241087 CMS
Regeneron Pharmaceuticals, Inc. $1,880.0005/16/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1213241089 CMS
Regeneron Pharmaceuticals, Inc. $470.0005/16/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1213241091 CMS
Regeneron Pharmaceuticals, Inc. $1,290.0005/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1213241075 CMS
Regeneron Pharmaceuticals, Inc. $1,290.0005/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1213241077 CMS
Regeneron Pharmaceuticals, Inc. $2,580.0005/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1213241079 CMS
Regeneron Pharmaceuticals, Inc. $5,160.0005/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1213241081 CMS
Regeneron Healthcare Solutions, Inc. $64.1904/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212990209 CMS
Regeneron Pharmaceuticals, Inc. $967.5004/04/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1213241069 CMS
Regeneron Pharmaceuticals, Inc. $322.5004/04/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1213241071 CMS
Regeneron Pharmaceuticals, Inc. $2,967.0004/04/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1213241073 CMS
Regeneron Pharmaceuticals, Inc. $118.6303/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213241063 CMS
Regeneron Pharmaceuticals, Inc. $120.3803/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213241065 CMS
Regeneron Pharmaceuticals, Inc. $63.5103/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213241067 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $54.8903/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251037060 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $99.1002/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251037062 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $47,444.97 42
PY2020 $15,821.82 6
PY2021 $56,251.00 8
PY2022 $14,791.36 9
PY2023 $58,185.22 27
PY2024 $52,889.63 36
PY2025 $64,594.97 69

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $9,321.07 49
PY2025 Principal investigator $395,826.31 80
PY2024 Recipient $2,108.27 3
PY2024 Principal investigator $395,296.92 14
PY2023 Recipient $3,571.25 49
PY2023 Principal investigator $885,632.26 40
PY2022 Recipient $5,968.65 67
PY2022 Principal investigator $692,259.47 27
PY2021 Recipient $12,745.08 79
PY2021 Principal investigator $153,369.16 17
PY2020 Recipient $9,992.30 59
PY2020 Principal investigator $193,345.38 21
PY2019 Recipient $4,593.29 41
PY2019 Principal investigator $659,874.48 34

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

129 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,045.60 12/19/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $125.00 12/18/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184142949
Recipient Regeneron Pharmaceuticals, Inc. $506.21 12/11/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120479
Recipient Regeneron Pharmaceuticals, Inc. $211.48 12/11/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120481
Recipient Regeneron Pharmaceuticals, Inc. $87.12 12/11/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120483
Recipient Regeneron Pharmaceuticals, Inc. $30.42 12/11/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120485
Recipient Regeneron Pharmaceuticals, Inc. $76.06 12/11/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120487
Recipient Regeneron Pharmaceuticals, Inc. $55.31 12/11/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120489
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,232.60 12/11/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142941
Recipient Regeneron Pharmaceuticals, Inc. $45.55 12/10/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120477
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,154.60 12/04/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,475.00 11/25/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142859
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,988.70 11/20/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142849
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,897.50 11/20/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142853
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,950.00 11/20/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142855
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,639.40 11/14/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142837
Recipient Regeneron Pharmaceuticals, Inc. $37.29 11/13/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184120471
Recipient Regeneron Pharmaceuticals, Inc. $243.73 11/13/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184120473
Recipient Regeneron Pharmaceuticals, Inc. $223.50 11/13/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184120475
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $906.25 11/13/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184142833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,614.25 11/11/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184142819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 11/11/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184142821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $81.25 11/11/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184142823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $775.00 11/11/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184142825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $81.25 11/11/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184142827
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,262.94 11/11/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184142829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,253.75 11/11/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184142831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,574.00 11/07/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142817
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,250.00 11/06/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184142789
Recipient Regeneron Pharmaceuticals, Inc. $293.78 10/23/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184120467
Recipient Regeneron Pharmaceuticals, Inc. $53.87 10/23/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184120469
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $279.50 10/23/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142741
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,294.50 10/23/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142743
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $795.74 10/23/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142745
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,475.00 10/23/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142747
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.30 10/16/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,312.15 10/09/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142705
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,550.00 10/03/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142575
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,475.00 10/03/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,223.95 10/03/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $906.25 09/25/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184142447
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,138.20 09/23/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142443
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,010.75 09/18/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142433
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,049.85 09/18/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142437
Recipient Regeneron Pharmaceuticals, Inc. $489.97 09/16/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120461
Recipient Regeneron Pharmaceuticals, Inc. $127.53 09/16/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120463
Recipient Regeneron Pharmaceuticals, Inc. $53.87 09/16/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184120465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,288.00 09/04/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142387
Recipient Regeneron Pharmaceuticals, Inc. $292.99 08/29/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120447
Recipient Regeneron Pharmaceuticals, Inc. $393.34 08/29/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120449
Recipient Regeneron Pharmaceuticals, Inc. $60.13 08/29/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120451
Recipient Regeneron Pharmaceuticals, Inc. $26.73 08/29/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120453
Recipient Regeneron Pharmaceuticals, Inc. $73.50 08/29/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120455
Recipient Regeneron Pharmaceuticals, Inc. $2.34 08/29/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120457
Recipient Regeneron Pharmaceuticals, Inc. $49.44 08/29/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120459
Recipient Regeneron Pharmaceuticals, Inc. $3.34 08/28/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120445
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,228.20 08/26/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142379
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,305.10 08/21/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142363
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,253.75 08/14/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184142347
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,366.40 08/14/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142351
Recipient Regeneron Pharmaceuticals, Inc. $53.87 08/13/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184120443
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 08/12/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184142341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $81.25 08/12/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184142343
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,456.40 08/07/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,614.25 08/06/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184142329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,262.94 08/06/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184142331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $775.00 08/04/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184142317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $81.25 08/04/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184142319
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,543.50 07/31/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,228.20 07/22/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,471.45 07/17/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,049.85 07/10/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142251
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,334.50 07/04/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142237
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $81.25 06/19/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184142213
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,850.00 06/19/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142215
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $48,880.00 06/19/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142217
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,342.50 06/19/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142219
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,900.00 06/19/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184142221
Recipient Regeneron Pharmaceuticals, Inc. $51.86 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120429
Recipient Regeneron Pharmaceuticals, Inc. $57.46 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120431
Recipient Regeneron Pharmaceuticals, Inc. $98.90 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120433
Recipient Regeneron Pharmaceuticals, Inc. $103.02 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120435
Recipient Regeneron Pharmaceuticals, Inc. $127.07 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120437
Recipient Regeneron Pharmaceuticals, Inc. $351.03 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120439
Recipient Regeneron Pharmaceuticals, Inc. $418.88 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120441
Recipient Regeneron Pharmaceuticals, Inc. $150.00 06/11/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120427
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,416.93 06/05/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184142129
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,723.75 06/05/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184142131
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $65.00 06/05/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184142133
Recipient Regeneron Pharmaceuticals, Inc. $310.40 06/01/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184120425
Recipient Regeneron Pharmaceuticals, Inc. $308.80 05/23/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120419
Recipient Regeneron Pharmaceuticals, Inc. $674.23 05/23/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120421
Recipient Regeneron Pharmaceuticals, Inc. $79.20 05/23/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120423
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,590.00 05/22/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184142073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,348.37 05/08/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184142025
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,175.00 05/08/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184142027
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,148.09 04/17/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY No dispute reported 06/30/2026 1184141881
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $130.00 04/17/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184141883
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,554.19 04/10/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184141847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,960.00 04/10/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184141849
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $195.00 04/10/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184141851
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $260.00 04/10/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184141853
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $65.00 04/10/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184141855
Recipient Regeneron Pharmaceuticals, Inc. $310.40 04/03/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184120417
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,489.84 03/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184141795
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,942.56 03/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184141797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $625.00 03/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY No dispute reported 06/30/2026 1184141799
Recipient Regeneron Pharmaceuticals, Inc. $53.87 03/25/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184120415
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $23,570.52 03/13/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184141765
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,298.17 02/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184141707
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $520.00 02/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184141709
Recipient Regeneron Pharmaceuticals, Inc. $360.44 02/16/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184120413
Recipient Regeneron Pharmaceuticals, Inc. $74.05 02/14/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184120411
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,707.37 02/13/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184141691
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,500.00 02/13/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY No dispute reported 06/30/2026 1184141693
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $276.25 02/13/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184141695
Recipient Regeneron Pharmaceuticals, Inc. $325.47 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120399
Recipient Regeneron Pharmaceuticals, Inc. $251.82 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120401
Recipient Regeneron Pharmaceuticals, Inc. $68.89 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120403
Recipient Regeneron Pharmaceuticals, Inc. $30.01 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120405
Recipient Regeneron Pharmaceuticals, Inc. $96.17 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120407
Recipient Regeneron Pharmaceuticals, Inc. $62.01 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120409
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,732.69 01/30/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184141475
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $23,154.01 01/30/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184141477
Recipient Regeneron Pharmaceuticals, Inc. $655.45 01/28/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120397
Recipient Regeneron Pharmaceuticals, Inc. $756.40 01/20/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184120395
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $260.00 01/16/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184141431
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,437.50 01/16/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184141433
Recipient Regeneron Pharmaceuticals, Inc. $53.87 01/15/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184120393